JAK Janus Kinase
K |
|||
| Zeile 1: | Zeile 1: | ||
{{up|PHA Biologicals}} | {{up|PHA Biologicals}} | ||
| + | {{qt|Baricitinib}} | ||
{{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}} | {{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}} | ||
| Zeile 17: | Zeile 18: | ||
{{tp|p=32342098|t=ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib |pdf=|usr=}} | {{tp|p=32342098|t=ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
'''Fedratinib''' | '''Fedratinib''' | ||
Version vom 11. April 2021, 19:30 Uhr
| PHA Biologicals |
| Baricitinib |
| 32584421 2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer. |
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19
| 32535597 2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. |
32385052 2020. ...The potential role of JAK inhibitors in the management of COVID-19.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
32584762 2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
32537890 2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.
32580895 2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Tofacitinib
32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
Fedratinib
| 32205092 ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |
Ruxolitinib
32450201 2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
32470486 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
32405693 2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
32518419 2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
32528040 2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
32585295 2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
32555296 2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
32593183 2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
32581810 2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
Jaktinib
32536632 2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.
Methotrexate mtx
32454489 2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
